Lippo-Backed Venturra Capital and Prenetics to Bring Personalized Medicine to Indonesia
Lippo-Backed Venturra Capital Signs MoU With Prenetics as a Strategic Investor / Partner for Indonesia
(firmenpresse) - HONG KONG, CHINA -- (Marketwired) -- 11/04/15 -- The Lippo Group, one of the largest conglomerates and the biggest healthcare provider in Indonesia, through its affiliate Venturra Capital, signed a Memordandum of Understanding (MoU) with , a Personalized & Precision Medicine Life Sciences company based in Hong Kong. Under the terms of the MoU, Venturra Capital will invest an undisclosed amount in the USD millions into Prenetics. In addition, the Lippo Group will act as a strategic partner for an initial period of 5-Years to offer personalized & precision medicine in Indonesia. Prenetics has developed its proprietary iGenes Pharmacogenomics test. Pharmacogenomics is the study of how genes affects a person''s response to drugs. iGenes is a non-invasive, saliva based test with a report ready to physicians within 48 hours. The iGenes report will identify the right drug, at the right dosage, tailored to a patient''s genetic make-up.
Lippo Group Director and Managing Partner of Venturra Capital, John Riady, stated, "Precision Medicine is the future of healthcare and we intend to make it accessible soon throughout Indonesia. Health care today needs reform as it is expensive, reactive, inefficient and focused largely on one-size fits-all treatments for chronic illness and cancer. An answer is personalized, predictive, and preventive medicine."
The CEO of Prenetics, Danny Yeung, stated, "Indonesia is a key market with a population of 250m, we are extremely grateful and excited to have Venturra Capital and the Lippo Group as our strategic partner. They are the clear leaders in health care in Indonesia. Every year millions suffer as a result of adverse drug reactions and is the 4th leading cause of deaths, a majority of these ADR''s are preventable. Together, it''s our vision to create a safer, healthier Asia."
Stefan Jung, Managing Partner of Venturra Capital, added, "It is quite rare to have a great scientific team with a great commercial team in Prenetics. The iGenes test offers a win-win scenario for all parties involved. The physician gets an incredible tool, patients receive personalized treatment, and payors save significantly on healthcare costs."
Andy A. Liu, Former Asia President IMS Health, noted, "Healthcare costs are increasing double-digits annually. In fact, IMS did a major study in 2013 and concluded wrong medications represent the #1 avoidable cost in healthcare with an over $200b USD opportunity, just in the USA."
"As leaders in their respective fields, each of these board members will provide significant value, perspectives and experience," said Danny Yeung.
is Professor, School of Biomedical Sciences; Head, Division of Genomics and Bioinformatics; Associate Director, CUHK-BGI Innovation Institute of Trans-omics; The Chinese University of Hong Kong.
is Head and Chair Professor, Department of Biomedical Sciences at City University of Hong Kong. Professor Yang is a co-founder of Prenetics.
is Former Division Head, Department of Clinical Pharmacology, Faculty of Medicine; The Chinese University of Hong Kong.
is an Associate Professor of Pharmaceutical Sciences at Southern Illinois University. Dr. Worthington notably worked on the Human Genome Project which was completed in 2003.
is an Assistant Professor of Medicine & Cardiology Specialist, Department of Medicine, Duke University of Medicine.
is Professor & Chair of Psychiatry, Creighton University of School of Medicine, St. Joseph''s Hospital and Medical Center.
is in private practice specializing in ADHD and Child Psychiatry.
is Founder and CEO of REAPRA. He was previously Founder and CEO of SMS Co Ltd (TSE 2175), one of the largest healthcare information platforms in Asia.
is a healthcare industry senior veteran, HKBIO Vice-Chairman and was previously President of Asia Pacific at IMS Health.
is a pharmaceutical industry senior veteran and was previously Chief Executive Officer, Healthcare Services for Zuellig Pharma.
Image
$213 billion in avoidable and unnecessary healthcare costs, affects millions of people (USA)
Company logo
Venturra Capital
Prenetics™
Venturra Capital is an independent venture capital firm backed by The Lippo Group. Venturra''s mission is to provide capital, operational empowerment, and market access to founders of innovative, industry-transforming, technology-enabled internet businesses. Venturra Capital will focus on Indonesia and Southeast Asia, and will invest in growth stage consumer technology-enabled companies including in the eCommerce, financial services, healthcare and education sectors.
Prenetics is a Personalized & Precision Medicine Life Sciences company specializing in Pharmacogenomics. Prenetics proprietary iGenes test enables physicians to help patients identify the right drug, right dosage and to list out potential adverse drug reactions, based on one''s genetic profile. Prenetics vision is to improve quality of life, prevent ADR''s and to save on healthcare costs by providing the tools essential for personalized medication management. For more information, visit
Image Available:
Colleen Wong
Tel: 852 - 2210 9585
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.11.2015 - 19:52 Uhr
Sprache: Deutsch
News-ID 1397028
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
HONG KONG, CHINA
Phone:
Kategorie:
Venture Capital
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Lippo-Backed Venturra Capital and Prenetics to Bring Personalized Medicine to Indonesia
"
steht unter der journalistisch-redaktionellen Verantwortung von
PreneticsTM (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
